Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
Open Access
- 30 April 2020
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 18 (2), 219-228
- https://doi.org/10.5217/ir.2019.00037
Abstract
Background/Aims: Intestinal fibrosis is a major complication of Crohn's disease (CD). The profibrotic protein transforming growth factor-beta (TGF-beta) has been considered to be critical for the induction of the fibrotic program. TGF-beta has the ability to induce not only the expression of extracellular matrix (ECM) including collagen, but also the production of plasminogen activator inhibitor-1 (PAI-1) that prevents enzymatic degradation of the ECM during the onset of fibrotic diseases. However, the significance of PAI-1 in the developing intestinal fibrosis has not been fully understood. In the present study, we examined the actual expression of PAI-1 in fibrotic legion of intestinal inflammation and its correlation with the abnormal ECM deposition. Methods: Chronic intestinal inflammation was induced in BALB/c mice using 8 repeated intrarectal injections of 2,4,6-trinitrobenzene sulfonic acid (TNBS). TM5275, a PAI-1 inhibitor, was orally administered as a carboxymethyl cellulose suspension each day for 2 weeks after the sixth TNBS injection. Results: Using a publicly available dataset (accession number, GSE75214) and TNBS-treated mice, we observed increases in PAI-1 transcripts at active fibrotic lesions in both patients with CD and mice with chronic intestinal inflammation. Oral administration of TM5275 immediately after the onset of intestinal fibrosis upregulated MMP-9 (matrix metalloproteinase 9) and decreased collagen accumulation, resulting in attenuation of the fibrogenesis in TNBS-treated mice. Conclusions: PAI-1-mediated fibrinolytic system facilitates collagen degradation suppression. Hence, PAI-1 inhibitor could be applied as an anti-fibrotic drug in CD treatment.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (17H05802)
- Japan Society for the Promotion of Science (19K017413)
- Tokai University
This publication has 35 references indexed in Scilit:
- Cellular and molecular mechanisms of intestinal fibrosisWorld Journal of Gastroenterology, 2012
- Epidemiology and Natural History of Inflammatory Bowel DiseasesGastroenterology, 2011
- PAI‐1 in tissue fibrosisJournal of Cellular Physiology, 2011
- A Novel Small Compound That Promotes Nuclear Translocation of YB-1 Ameliorates Experimental Hepatic Fibrosis in MiceOnline Journal of Public Health Informatics, 2011
- Integration of non-SMAD and SMAD signaling in TGF-β1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cellsThrombosis and Haemostasis, 2008
- Emerging insights into Transforming growth factor Smad signal in hepatic fibrogenesisGut, 2007
- Targeted Deletion of Metalloproteinase 9 Attenuates Experimental Colitis in Mice: Central Role of Epithelial-Derived MMPGastroenterology, 2005
- A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-κBGastroenterology, 2003
- Interferon-γ Interferes with Transforming Growth Factor-β Signaling through Direct Interaction of YB-1 with Smad3Online Journal of Public Health Informatics, 2003
- PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma modelBiochemical and Biophysical Research Communications, 2002